Few veterinary studies have evaluated the response to chemotherapy treatment of canine intranasal tumours, while many have focused on the efficacy of radiation therapy. Given the higher costs and limited access to radiation therapy, alternative treatment options are needed. The study describes a cohort of dogs with histologically confirmed intranasal tumours treated with chemotherapy as a sole therapy. This retrospective study was conducted using data from the 
| INTRODUCTION
Canine intranasal tumours are rare, comprising from 1% to 2% of all canine tumours. [1] [2] [3] [4] Carcinomas account for approximately two thirds of these tumours, while sarcomas comprise the bulk of the remainder. 3, 5, 6 Malignant nasal tumours are typically locally invasive causing bony destruction and most clinical signs relate to the location of the primary disease. The most frequently reported clinical signs include epistaxis, sneezing and nasal discharge. 2, 4, 7 Metastatic disease is uncommon at diagnosis and despite up to 46% of dogs having metastatic disease at the time of death, death due to metastatic disease is rare. 8 More frequently, dogs die or are euthanized because of persistent clinical signs or extension of the local tumour. [3] [4] [5] [6] [7] [8] Various treatment options have been investigated; however long term survival remains elusive. Megavoltage radiation is considered the "gold standard" with median survival times ranging from 8 to 23 months. 9, 10 Other treatments have included surgery, 11 cryosurgery, 12 combinations of surgery and radiation, 10, 13, 14 chemoradiotherapy, 15, 16 and chemotherapy. 17, 18 To date, only two studies have reported chemotherapy as a singular treatment. One reported a response rate of 27% to cisplatin administered every 3 weeks for 11 dogs. Response was based on radiographic findings and a median survival time of 20 weeks or 140 days (range 8-128 weeks) was reported. 17 The other study assessed an alternating carboplatin and doxorubicin protocol with adjunctive piroxicam similar to that reported in this study. 18 That study reported a computed tomography based, objective response rate of 75% with a complete remission rate of 50% and median survival time of 220 days (range 150-960). 18 The aim of this study was to describe a cohort of dogs, diagnosed with intranasal neoplasia and treated with chemotherapy as a sole therapy. The study assessed the efficacy and tolerability of a modified version of the previously reported combination chemotherapy protocol. 18 Secondary aims were to compare the survival for the various tumour types and the effect of tumour stage at diagnosis on overall survival.
| METHOD AND MATERIALS

| Inclusion criteria
The medical records at Melbourne Veterinary Specialist Centre (MVSC) were searched from January 1995 to January 2017 for all dogs diagnosed with histologically confirmed, malignant nasal neoplasia. Dogs were eligible for inclusion if there was intention to treat with the study chemotherapy protocol and at least one treatment was administered. Information regarding breed, weight, sex, age at diagnosis, presenting signs (sneezing, nasal discharge, discharge type, presence of facial distortion and appetite) and final histological diagnosis were obtained. The Modified Adams System was used to stage the dogs (Table 1) . 19 In cases with incomplete data, an estimate of the minimum stage was used. Magnetic resonance imaging (MRI) images were reviewed, when available, to provide information on tumour stage. Endoscopy reports and radiographs were also reviewed to assist staging when MRI was not performed. When the endoscopy procedure report described nasopharyngeal involvement, the tumour was staged minimum T3(a). 
| Chemotherapy protocol
| Statistical analysis
Overall survival was defined from the date of diagnosis to the date of Table 2 . Information regarding age, sex, weight, breed and presenting signs are presented in Table 3 .
Tumour stage was determined for all dogs; T1 (n = 9), T2 (n = 3), T3 (n = 5), T3a (n = 8), T4 (n = 4). Magnetic resonance (MR) images were utilized for 14 of these dogs, while endoscopy reports noted a mass at the nasopharynx in a further four dogs. Three dogs were 
| Chemotherapy protocol
Fifteen (52%) dogs received the prescribed study protocol. One dog received seven total treatments (5 carboplatin, 2 doxorubicin-CCDCDCC) with the reasoning not described in the clinical records. 
| Patient outcomes
Date of final outcome was available for 26 (90%) dogs. Two dogs were censored when they were lost to follow-up at 93 and 173 days respectively. Both dogs had PD and for the purpose of statistical analysis were considered to have died from tumour-related causes. One dog was lost to follow-up after the first doxorubicin treatment and was censored at 21 days.
Of the 26 dogs with a known date of final outcome, 22 dogs died because of the tumour, three dogs died because of other causes, while one dog was censored at 83 days when radiation was received. The dog who received radiation was considered to have died because of the tumour at 83 days for statistical analysis. Twenty-one dogs were euthanized because of signs attributed to the tumour. The cause for euthanasia or death of the 25 dogs is shown in Table 5 .
The median overall survival for the cohort was 234 days (95% CI 84-384), range 12 to 1698, with the survival curve presented in No dogs were reported to die from distant metastatic disease.
Although no dogs were submitted for post mortem examination, the clinical signs were more suggestive of progressive local disease.
| DISCUSSION
The study population was similar to previous studies of canine nasal tumours with regard to body weight, age and sex. Sneezing, nasal discharge and epistaxis were common in this cohort with prevalence similar to previous reports. 4 Previously reported prognostic factors include age at diagnosis, Intranasal sarcoma has been reported to carry a better prognosis than carcinoma is some studies, 3 but this finding has not been supported by others. 5, 19, 24 In this study, there were only four dogs with sarcoma making statistical analysis less reliable than studies with larger cohorts. Further, there were no chondrosarcomas in this cohort, the nasal tumour previously reported to have the most favourable prognosis. 3 The four dogs with sarcomas lived from 304 to 816 days and while they appeared to have a better survival than dogs with carcinomas, the finding was not significant (P = 0.077).
The chemotherapy protocol was based on the protocol reported by Langova et al (2004) . 18 This study utilized two fewer chemotherapy treatments with a similar overall survival. While, further studies would be required to identify the optimal number of treatments in the initial protocol, the results support the protocol modification.
Similarly to Langova et al (2004) , 18 No attempt was made to attribute significance to the administration of the various rescue treatments. Too few dogs were following the treatment protocol. However, it was often unclear if piroxicam was continued long term and therefore the full impact of piroxicam treatment could not be determined.
Metastatic disease was not assessed in most patients, therefore the effect of metastatic disease on survival could not be fully elucidated in this study. However, as the majority of dogs died because of the effects of the primary tumour, the impact of metastatic disease was likely to be low.
Response to treatment was subjective because of the lack of repeat imaging. Assessment of response was based on owner-reported and clinician-observed clinical signs. While subjective clinical response might be a reasonable surrogate for definitive, imaging confirmed response in a retrospective study, this was a limitation of the study.
This paper supports the use of chemotherapy for intranasal tumours. While radiation remains the current gold standard therapy, treatment with chemotherapy appears to provide a significant survival benefit when compared with palliative care alone. 4 Chemotherapy is much less costly than current megavoltage radiation treatment and is more widely available. In many countries, distant travel is required to access radiation facilities, a situation often declined by owners. Chemotherapy could be considered as first line therapy for dogs with intranasal tumours when access to megavoltage radiation is limited or costprohibitive.
Some consideration may be afforded a combination approach to the management of nasal tumours in the future. Chemotherapy could be considered as a neo-adjuvant therapy prior to radiation therapy or for use in a rescue setting when clinical signs recur. Studies assessing the potential combination of radiation and chemotherapy treatments may help to improve the overall survival for dogs with intranasal tumours.
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